RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Key Takeaways Rocket Pharmaceuticals received FDA RMAT designation for its RP-A601 gene therapy candidate. The RMAT tag was granted based on encouraging phase I safety and efficacy data for a heart failure disease. Treatment with RP-A601 was generally safe and well-tolerated in the ongoing phase I study.Rocket Pharmaceuticals (RCKT) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adeno-associated virus (AAV)-based gene therapy, RP-A60 ...